HEC Pharm Co., Ltd. – FDA 483, Nov 21, 2025
An FDA inspection of HKC Pharm Co. Ltd. in Yidu, Hubei, an API manufacturer, revealed significant deficiencies across multiple areas. Observations included inadequately validated analytical methods for impurities, unqualified laboratory instruments and software impacting data integrity, and unvalidated culture media for microbial monitoring. Additionally, manufacturing equipment was not properly maintained, and the manufacturing computer system was inadequately qualified, leading to product loss.
- Office
- Office of Partnerships
- Person
ID · 5f83c498-95d0-4f58-bda2-70769715076b
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.